🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to the winners of the IJMS 2023 Best Paper Award! "The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis" By Mahshid Ghasemi et al. Read more here: mdpi.com/1422-0067/22/2…

Fantastic talk by last-minute stand-in Dejan K Filipas: Impact of a peritoneal bladder flap (Uwe-Michl-Technique) during #RARP, RCT findings from Martini-Klinik am UKE Markus Graefen Derya Tilki, MD Pierre Tennstedt @sophieknipper #AUA24 #pcsm UKE Hamburg Randi Pose

Beauty of Numbers [explanation: buff.ly/3NJprVW]

I'm happy to share my editorial in the special issue Immunotherapies for Cancer. mdpi.com/journal/ijms/s… Advances, Limitations and Future Challenges in the Management of Immunotherapy for Hematological Diseases and Solid Tumors mdpi.com/2295542 #mdpiijms via IJMS MDPI

My new special issue in the #IJMS journal at #MDPI is about special cells, the macrophages. Everyone is cordially invited to contribute here. I am happy about your contributions. mdpi.com/journal/ijms/s…

My special issue still accepting manuscripts! In Honor of Elie Metchnikoff, a Nobel Prize Winner, Who Discovered Macrophages as Phagocyte Cells Involved in the Process of Innate Immunity mdpi.com/si/171743 #mdpiijms via IJMS MDPI

Cloud-Anwendungen - Hacker-Angriff auf Microsoft war gravierend | tagesschau.de tagesschau.de/investigativ/s…

Want to learn more about prostate cancer ? And how we can use PSMA RLT ? Come to todays symposium with the outstanding clinicians Derya Tilki, MD Prof Joe O'Sullivan and Prof Maria de Santis European Association of Nuclear Medicine (EANM) #eanm2023

Don't forget, there's still time. Deadline for manuscript submissions: 31 October 2023 In Honor of Elie Metchnikoff, a Nobel Prize Winner, Who Discovered Macrophages as Phagocyte Cells Involved in the Process of Innate Immunity mdpi.com/si/171743 #mdpiijms via IJMS MDPI

Don't forget, there's still time. Deadline for manuscript submissions: 31 December 2023 The Role of Macrophages in Cancers mdpi.com/si/179579 #mdpiijms via IJMS MDPI

(1/5) Unfassbar: Ursula von der Leyen kassiert weiter den Umweltschutz in der #Landwirtschaft! Trotz fehlender Mehrheit bei den Mitgliedstaaten beschließt die @EU_commission heute ökologische Anforderungen auszusetzen, die in der #GAP geregelt sind. #GLÖZ8

If your code only exists in your laptop, you have 4 big problems: - 🔥Safety - ✉️Sharing - 🦕History - 🤝Collaboration Github solves all of them. And it's less complicated than you think. 🧵Here is a thread on how to use it right now on your project! (6 steps)

Some myths about PSA screening mskcc.org/news/myths-abo…

🎉 New section in the R Graph Gallery!! Everything you need to know about... ✨Waffle Charts ✨ - Beginner tutorials - Expert figures by @BjnNowak and Muhammad Azhar Thanks to Joseph for the hard work!

Motor augmentation, involving motorized wearable devices like exoskeletons and robotic body parts, may enhance human capabilities beyond biological limits x.com/visualfeastwan…

🔥 Finally! Just launched the R color palette finder 🚀 🎨 Explore 2500+ palettes, see them in action, get the ggplot2 code. ➡️ r-graph-gallery.com/color-palette-… 🙏 Joseph and Emil Hvitfeldt for the paletteer package! Useful? Bug? Feature request? Let me know!

My new special issue is now open for submissions! Genetic Considerations in the Evolving Treatment Landscape of Hormone-Sensitive and Hormone-Resistant Prostate Cancer mdpi.com/si/214495 #mdpiijms via IJMS MDPI

The Role of Macrophages in Cancers mdpi.com/si/179579 #mdpiijms via IJMS MDPI Please Share. The deadline for submissions to this special issue is fast approaching.

Genetic Considerations in the Evolving Treatment Landscape of Hormone-Sensitive and Hormone-Resistant Prostate Cancer mdpi.com/si/214495 #mdpiijms via IJMS MDPI Please share. The deadline for submissions to this special issue is 30 November.

Compared to Goteborg 2 screening (PSA then MRI; NEJM) and PROSCREEN (PSA then marker then MRI; JAMA), BARCODE PRS based screening found fewer significant cancers (grade group 2+), more insignificant cancer and biopsied more men (the trifecta!). nejm.org/doi/full/10.10…